GRK2 and type 2 diabetes mellitus: To date, the impact of a GRK2 inhibitor on human therapy cannot be foreseen despite the evidence that short peptides derived from the HJ loop of GRK2 [118] possess promising metabolic effects in animal models of Type 2 diabetes and IRES, as well as in endothelial function and heart failure.